Impact of a Dietary Supplement Containing 1,3-Dimethylamylamine on Blood Pressure and Bloodborne Markers of Health: a 10-Week Intervention Study by Whitehead, Paul et al.
Kinesiology and Nutrition Sciences Faculty
Publications Kinesiology and Nutrition Sciences
2-1-2012
Impact of a Dietary Supplement Containing
1,3-Dimethylamylamine on Blood Pressure and
Bloodborne Markers of Health: a 10-Week
Intervention Study
Paul Whitehead
Brian Schilling
University of Nevada, Las Vegas, brian.schilling@unlv.edu
Tyler Farney
Richard Bloomer
Follow this and additional works at: http://digitalscholarship.unlv.edu/kns_fac_articles
Part of the Pharmacy and Pharmaceutical Sciences Commons, and the Sports Sciences
Commons
This Article is brought to you for free and open access by the Kinesiology and Nutrition Sciences at Digital Scholarship@UNLV. It has been accepted
for inclusion in Kinesiology and Nutrition Sciences Faculty Publications by an authorized administrator of Digital Scholarship@UNLV. For more
information, please contact digitalscholarship@unlv.edu.
Citation Information
Whitehead, P., Schilling, B., Farney, T., Bloomer, R. (2012). Impact of a Dietary Supplement Containing 1,3-Dimethylamylamine on
Blood Pressure and Bloodborne Markers of Health: a 10-Week Intervention Study. Nutrition and Metabolic Insights, 5 33-39.
http://digitalscholarship.unlv.edu/kns_fac_articles/21
Nutrition and Metabolic Insights 2012:5 33–39
doi: 10.4137/NMI.S8885
This article is available from http://www.la-press.com.
© the author(s), publisher and licensee Libertas Academica Ltd.
This is an open access article. Unrestricted non-commercial use is permitted provided the original work is properly cited.
Open Access
Full open access to this and 
thousands of other papers at 
http://www.la-press.com.
Nutrition and Metabolic Insights
O r I g I N A L  r e S e A r c h
Nutrition and Metabolic Insights 2012:5 33
Impact of a Dietary supplement containing  
1,3-Dimethylamylamine on Blood pressure and Bloodborne  
Markers of Health: a 10-Week Intervention study
Paul N. Whitehead, Brian K. Schilling, Tyler M. Farney and richard J. Bloomer
cardiorespiratory/Metabolic Laboratory, The University of Memphis, Memphis, TN 38152, USA.
corresponding author email: rbloomer@memphis.edu
Abstract
Background: 1,3-dimethylamylamine is a commonly used ingredient within dietary supplements. Our prior work with this agent 
­indicates­a­transient­increase­in­blood­pressure­(systolic­in­particular)­following­oral­ingestion­of­a­single­dosage,­but­no­significant­
increase in resting blood pressure following chronic ingestion. Moreover, intervention studies involving both two and eight weeks of 
treatment­with­finished­products­containing­1,3-dimethylamylamine­indicate­minimal­or­no­change­in­bloodborne­markers­of­health.­
The­present­study­sought­to­extend­these­findings­by­using­a­10-week­intervention­trial­to­determine­the­change­in­selected­markers­of­
health in a sample of men.
Methods: 25 healthy men were randomly assigned to either a placebo (n = 13) or to a supplement containing 1,3-dimethylamylamine 
(n =­12)­for­a­period­of­10­weeks.­Before­and­after­the­intervention,­resting­blood­pressure­and­heart­rate­were­measured,­and­blood­
samples were collected for determination of complete blood count, metabolic panel, and lipid panel.
Results:­No­significant­differences­were­noted­between­conditions­for­blood­pressure­(P .­0.05),­although­systolic­blood­pressure­
increased approximately 6 mmHg with the supplement (diastolic blood pressure decreased approximately 4 mmHg). A main effect for 
time was noted for heart rate (P =­0.016),­with­values­decreasing­from­pre­to­post­intervention.­There­were­significant­main­effects­
for time for creatinine (increased from pre to post intervention; P =­ 0.043)­ and­ alkaline­ phosphatase­ (decreased­ from­pre­ to­ post­
intervention; P =­0.009),­with­no­condition­differences­noted­(P .­0.05).­There­was­a­significant­interaction­noted­for­low­density­lipo-
protein cholesterol (LDL-C) (P =­0.043),­with­values­decreasing­in­the­supplement­group­from­pre­to­post­intervention­approximately­
7 mg ⋅ dL−1 (P =­0.034).­No­other­effects­of­significance­were­noted­for­bloodborne­variables.
Conclusion:­These­data­indicate­that­a­dietary­supplement­containing­1,3-dimethylamylamine­does­not­result­in­a­statistically­signifi-
cant increase in resting heart rate or blood pressure (although systolic blood pressure is increased ∼6 mmHg with supplement use). The 
supplement does not negatively impact bloodborne markers of health. Further study is needed involving a longer intervention period, 
a larger sample size, and additional measures of health and safety.
Keywords: nutritional supplements, chronic effects, 1,3-dimethylamylamine
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Background
While somewhat controversial, 1,3-dimethylam-
ylamine has been suggested to be a component of 
the Pelargonium graveolens plant;1 a simple aliphatic 
amine2 with sympathomimetic properties. Aside from 
1,3-dimethylamylamine, common chemical names 
cited for this agent include 2-amino-4-methylhexane, 
1,3-dimethylpentylamine, methylhexaneamine, and 
4-methyl-2-hexylamine. It is also known by the trade-
marked name geranamine™ (Proviant Technologies, 
Inc,­2005:­US­trademark­number:­78542697).
The use of 1,3-dimethylamylamine is wide-
spread within the dietary supplement industry, 
in particular as a component of weight loss and 
pre-workout products. A recent report published 
by the Human Performance Resource Center 
(http://www.humanperformanceresourcecenter.org) 
provides­ a­ detailed­ listing­ of­ close­ to­ 100­ products­
believed to contain 1,3-dimethylamylamine. While 
anecdotal reports of improved exercise performance 
are common, we are aware of only one published 
experiment designed to investigate the ergogenic 
properties of 1,3-dimethylamylamine alone or in 
combination with caffeine,3 which noted little impact 
on aerobic exercise performance. Regardless of 
actual ergogenic effectiveness, the overall safety of 
the ingredient needs to be considered.
In our recent article in which 1,3-dimethylamylamine 
was administered alone and in combination with 
caffeine in a single dosage to healthy men and 
women,4 we noted that heart rate was unaffected by 
treatment, but blood pressure was elevated when 
consuming 1,3-dimethylamylamine—generally in a 
dose-dependent manner. The peak percent change in 
systolic (∼20%)­ and­ diastolic­ (∼17%)­ blood­ pressure­
was­ noted­ at­ 60­ minutes­ following­ ingestion­ of­ the­
combination­ of­ 250­ mg­ of­ caffeine­ and­ 75­ mg­ of­
1,3-dimethylamylamine. A second study investigated 
the blood pressure and heart rate response of 
1,3-dimethylamylamine and caffeine alone and in 
combination (compared to a placebo) in a sample of 
endurance trained men and women before, during, and 
following strenuous exercise.3 In this study, heart rate was 
relatively similar across conditions, and blood pressure was 
generally highest for caffeine and 1,3-dimethylamylamine 
alone compared to other conditions.
Research on the use of 1,3-dimethylamylamine in 
combination­ with­ other­ ingredients­ within­ finished­
products­ demonstrated­ first­ that,­ in­ terms­ of­ acute­
changes in blood pressure and heart rate, dietary sup-
plements containing 1,3-dimethylamylamine result in 
minimal change in heart rate but do increase  systolic 
blood pressure transiently.5,6­ Second,­ in­ terms­ of­
chronic changes in blood pressure and heart rate, we 
have noted little or no change in resting measures after a 
two-week5 or eight-week7 intervention. Third, in terms 
of chronic changes in bloodborne biomarkers of health 
and safety, we have noted little or no change in mea-
sures after a two-week5 or eight-week7 intervention.
Collectively,­ the­ above­ findings­ indicate­ r­elative­
safety of this ingredient, at least with regard to the 
included outcome measures. However, due to the 
transient increase in systolic blood pressure, the need 
exists to further evaluate the potential for this agent 
to raise resting blood pressure following a longer 
period of chronic intake. The present study sought 
to­ extend­ our­ prior­ findings­ related­ to­ the­ use­ of­
1,3-dimethylamylamine in a combined product by 
using­ a­ 10-week­ intervention­ trial­ to­ determine­ the­
change in selected markers of health and safety in a 
sample of healthy men.
Methods
Subjects
Thirty resistance-trained men were recruited from the 
local university campus and surrounding community. 
Sample­ size­was­chosen­based­on­ studies­of­ similar­
magnitude and scope; however a power analysis was 
not performed a priori.­ Subjects­ were­ self-reported­
non-smokers, and did not have cardiovascular or met-
abolic disease. Health history, drug and dietary sup-
plement usage, and physical activity questionnaires 
were­completed­by­subjects.­Subjects­were­instructed­
to maintain their current exercise training and dietary 
intake programs throughout the study period with the 
exception of refraining from strenuous exercise during 
the­48­hours­prior­to­each­lab­session.­Subjects­did­not­
use dietary supplements, with the exception of meal 
replacements and protein powders, during the study 
period.­The­study­was­approved­by­the­University­of­
Memphis­Committee­for­Human­Subject­Research.
Design
This study involved a randomized, placebo-controlled 
design. Although the study was also double-blinded, 
the stimulant effects of the supplement suggest that 
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blinding­ from­ the­ subject­ standpoint­ is­ essentially­
lost.­During­the­first­visit­ to­the­laboratory,­subjects­
provided written informed consent and completed 
health and physical activity questionnaires.
Lab protocol
Subjects­ reported­ to­ the­ lab­ in­ the­ morning­ hours­
following a minimum of an eight-hour overnight 
fast,­before­and­after­the­10-week­intervention.­Upon­
arrival­to­the­lab,­subjects­rested­quietly­in­a­supine­
position­for­10­minutes.­Heart­rate­(via­palpation)­and­
blood pressure (via stethoscope) were then measured 
and recorded. A blood sample was then obtained from 
subjects­(∼20­mL).­Blood­was­processed­and­sent­to­
Laboratory Corporation of America for analysis of 
complete blood count, comprehensive metabolic 
panel, and lipid panel. The complete blood count was 
determined using an automated cell counter (Coulter 
LH750).­ The­ comprehensive­ metabolic­ panel­ was­
determined­ using­ automated­ procedures­ (Roche/
Hitachi Modular). The lipid panel was determined 
using­enzymatic­procedures­(Roche/Hitachi­­Modular).­
To­ better­ characterize­ subjects,­ body­ mass­ (using­
an electronic scale) and body composition (using 
dual energy x-ray absorptiometry) was measured. 
These same procedures were used both pre and post 
intervention­for­all­subjects.
Physical activity and dietary intake
Subjects­were­asked­to­maintain­their­usual­physical­
activity and dietary patterns and to record all food 
and drink consumed during the seven days prior to 
each lab session (both pre and post intervention). 
All records were analyzed for total calories, protein, 
carbohydrate, fat, vitamin C, vitamin E, and vitamin 
A­(Food­Processor­SQL,­version­9.9,­ESHA­Research,­
Salem,­OR).
conditions
The two conditions consisted of a placebo powder 
(microcrystalline cellulose, silicon dioxide, citric acid, 
natural­ flavor,­ acesulfame-K,­ sucralose,­ vegetable­
stearate, chlorophyll for coloring; at a volume equal 
to that of the supplement) and a dietary supplement 
containing a proprietary blend of 1,3-dimethylam-
ylamine, caffeine, creatine monohydrate, β-alanine, 
schinzandrol A, and arginine alpha-ketoglutarate 
(Jack3d™,­USPlabs,­LLC.­Dallas,­TX).­Subjects­were­
instructed to consume 1–3 servings on each workout 
day,­30­minutes­prior­ to­ their­exercise­ session.­The­
mean­number­of­workout­days­per­week­for­subjects­
was four and the supplement was not consumed on 
non-exercise­ days.­ Subjects­ reported­ back­ to­ the­
laboratory as needed for receipt of an additional con-
tainer­ of­ their­ assigned­ condition.­Both­ the­ supple-
ment and placebo powder were to be mixed into eight 
ounces of water and both had a similar lemon-lime 
taste.­Subjects­ingested­the­assigned­condition­for­the­
duration­of­the­10-week­study­period.
Statistical analysis
Data were analyzed using a 2 (condition) × 2 (time) 
factorial analysis of variance (ANOVA) with use of 
Fisher’s­LSD.­Data­are­presented­as­mean­± standard 
deviation.­All­analyses­were­performed­using­PASW­
statistical­ software­ (version­ 18).­ Statistical­ sig-
nificance­ was­ set­ at­P #­ 0.05.­ Standardized­ effect­
sizes­ (ES)­were­calculated­ for­means­comparisons.8 
Effect­size­magnitudes­can­be­interpreted­as­follows:­
0.2­small,­0.6­moderate,­and­1.2­large.
Results
Although­30­subjects­began­the­study,­only­25­subjects­
successfully­ completed­ all­ lab­ sessions.­ Of­ the­ five­
subjects­who­failed­ to­complete­ the­study,­ two­were­
initially assigned to the placebo and three were initially 
assigned­to­the­supplement.­One­subject­in­the­supple-
ment­group­was­injured­while­training­and­was­unable­
to complete the intervention, and thus was excluded 
from­analysis.­The­ remaining­ four­ subjects­ failed­ to­
complete­all­testing­due­to­personal­reasons.­These­five­
subjects­are­not­included­in­the­analyses.­Additionally,­
two­subjects­in­the­placebo­group­were­unable­to­pro-
vide blood samples pre- and post intervention and are 
thus excluded from the bloodborne variable analysis. 
No­subjects­reported­adverse­events­attributable­to­the­
supplement or placebo.
Of­the­25­subjects­in­the­analysis,­self­reported­use­
data­of­subjects­indicate­that­the­mean­number­of­scoops­
of the supplement consumed on training days was 
2.4 ±­0.3­(2­subjects­=­3­scoops;­7­­subjects­= 2 scoops; 
3­ subjects­ = 1.5 scoops), which was greater than 
(P =­0.0003)­the­mean­number­of­scoops­of­the­pla-
cebo consumed (1.7 ±­ 0.4;­ 7­ ­subjects­ = 2 scoops; 
3­subjects­=­1.5­scoops;­3­­subjects­=­1­scoops).­­Subject­
characteristics are presented in Table 1.
Whitehead et al
36 Nutrition and Metabolic Insights 2012:5
Blood pressure and heart rate data
No­significant­differences­were­noted­between­condi-
tions for blood pressure (P .­0.05).­However,­systolic­
blood pressure increased approximately 6 mmHg 
with the supplement, while diastolic blood pressure 
decreased approximately 4 mmHg from pre to post 
intervention. A main effect for time was noted for 
heart rate (P =­0.016,­ES­= 1.1), with values decreas-
ing­from­pre­to­post­ intervention.­No­other­findings­
were­ of­ statistical­ significance­ (P .­ 0.05).­ Blood­
pressure and heart rate data are presented in Table 1.
Bloodborne data
There­were­significant­main­effects­for­time­for­creati-
nine (increased from pre to post intervention; P =­0.043,­
ES­= 1.1) and alkaline phosphatase (decreased from 
pre to post intervention; P =­ 0.009,­ES­=­ 0.5),­with­
no condition differences noted (P .­0.05).­There­was­
a­ significant­ interaction­ noted­ for­ low­ density­ lipo-
protein cholesterol (LDL-C) (P =­0.043),­with­values­
decreasing in the supplement group from pre to post 
intervention approximately 7 mg ⋅ dL−1 (P =­ 0.034,­
ES­=­0.9).­No­other­effects­of­statistical­significance­
were noted for bloodborne variables. Data are pre-
sented in Table 2 for complete blood count, Table 3 
for metabolic panel, and Table 4 for lipid panel.
Dietary data
There­was­a­significant­main­effect­for­time­for­dietary­
fiber­ (P =­ 0.018,­ ES­=­ 0.8),­which­ decreased­ from­
pre to post intervention. A main effect for time was 
also noted for dietary selenium (P =­0.032,­ES­=­0.8),­
which increased from pre to post intervention. Dietary 
data are presented in Table 5.
Table 1. characteristics of men assigned to supplement (N = 12) or placebo (N = 13) for ten weeks.
Variable supplement placebo
pre post pre post
Age (years) 23 ± 2.9 NA 21.9 ± 2.3 NA
Weekly resistance training (hrs) 5.2 ± 1.9 NA 4.4 ± 1.7 NA
resistance training history (yrs) 3.6 ± 3.5 NA 4.2 ± 1.7 NA
Body weight (kg) 76.9 ± 9.1 77.2 ± 10.1 80.7 ± 15.6 82.0 ± 16.1
DeXA total body fat (%) 17.0 ± 4.9 15.8 ± 5.2 15.6 ± 9.2 16.2 ± 9.7
heart rate (bpm)* 61.5 ± 12.9 58.4 ± 6.4 61.4 ± 10.6 55.2 ± 8.3
Systolic blood pressure (mmhg) 117.8 ± 10.6 124.4 ± 19.3 121.2 ± 12.3 119.6 ± 8.6
Diastolic blood pressure (mmhg) 76.3 ± 9.2 72.0 ± 7.9 76.0 ± 8.4 75.3 ± 5.8
notes: Values are mean ± SD. *Significant main effect for time (P , 0.05).
Table 2. complete blood count data for men assigned to supplement (N = 12) or placebo (N = 11) for ten weeks.
Variable supplement placebo
pre post pre post
WBc (103 ⋅ μL−1) 5.8 ± 1.5 5.2 ± 1.0 5.2 ± 1.7 4.8 ± 1.1
rBc (106 ⋅ μL−1) 5.1 ± 0.4 4.9 ± 0.3 4.8 ± 0.3 4.8 ± 0.3
hemoglobin (g ⋅ dL−1) 15.3 ± 1.0 14.8 ± 0.9 14.6 ± 0.7 14.6 ± 0.8
hematocrit (%) 45.4 ± 2.6 44.2 ± 2.0 43.8 ± 1.6 43.3 ± 2.0
McV (fL) 89.8 ± 4.9 89.7 ± 4.7 91.2 ± 3.3 90.2 ± 4.0
Mch (pg) 30.3 ± 2.2 30.1 ± 2.2 30.4 ± 1.7 30.4 ± 1.3
Mchc (g ⋅ dL−1) 33.7 ± 0.9 33.6 ± 0.8 33.4 ± 1.1 33.6 ± 0.6
rDW (%) 13.0 ± 0.6 12.9 ± 0.4 13.1 ± 0.4 12.9 ± 0.6
Platelets (103 ⋅ μL−1) 244.5 ± 32.5 234.9 ± 35.3 200.6 ± 42.3 194.6 ± 33.1
Neutrophils (%) 49.8 ± 9.3 47.6 ± 6.6 50.5 ± 11.8 46.1 ± 11.2
Lymphocytes (%) 37.1 ± 8.1 37.6 ± 6.9 35.9 ± 11.3 39.7 ± 11.6
Monocytes (%) 9.2 ± 1.7 9.8 ± 2.1 10.2 ± 2.7 10.4 ± 1.4
eosinophils (%) 3.4 ± 2.5 4.3 ± 3.4 2.8 ± 1.8 3.2 ± 1.7
Basophils (%) 0.5 ± 0.5 0.7 ± 0.5 0.6 ± 0.7 0.6 ± 0.7
notes: Values are mean ± SD. No differences of statistical significance noted (P . 0.05).
1,3-dimethylamylamine and health
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Discussion
Our data indicate that a dietary supplement contain-
ing­ 1,3-dimethylamylamine­ does­ not­ significantly­
increase resting heart rate or blood pressure (although 
systolic blood pressure increased ∼6 mmHg with the 
supplement). Moreover, the supplement does not 
adversely impact bloodborne biomarkers of health, 
but rather, results in a decrease in LDL-C. These 
findings­are­in­reference­to­a­small­sample­of­healthy­
men who exercise regularly. Due to the fact that our 
sample size is small, additional well-designed experi-
ments of similar scope, inclusive of larger sample 
sizes,­ are­ needed­ to­ extend­ the­ findings­ presented­
within. It is only through such work that our ability 
to­­generalize­these­findings­to­the­population­at­large­
will be possible.
These data extend our prior work using 1,3-
dimethylamylamine in combination with other ingre-
dients, including those considered to be stimulants.5,7 
Collectively, these data provide some support for the 
relative safety of this agent; at least with regards to 
the measured outcomes used in this study, as well as 
others which we have conducted. Despite this, more 
work is needed involving a longer intervention period 
and the inclusion of additional measures of health 
(eg, toxicology, cardiac function), to more fully elu-
cidate the safety of oral 1,3-dimethylamylamine 
ingestion. Additionally, since products containing 
Table 3. comprehensive metabolic panel data for men assigned to supplement (N = 12) or placebo (N = 11) for ten weeks.
Variable supplement placebo
pre post pre post
glucose (mg ⋅ dL−1) 92.3 ± 5.9 90.1 ± 8.9 83.8 ± 7.5 88.5 ± 6.3
BUN (mg ⋅ dL−1) 17.0 ± 5.3 17.0 ± 4.7 15.6 ± 2.5 18.0 ± 3.4
creatinine (mg ⋅ dL−1)* 1.1 ± 0.1 1.2 ± 0.1 1.1 ± 0.1 1.1 ± 0.1
BUN:creatinine 15.3 ± 3.8 14.8 ± 4.1 14.7 ± 3.1 16.0 ± 2.6
Sodium (mmol ⋅ L−1) 141.3 ± 1.7 141.3 ± 1.9 142.0 ± 1.3 140.9 ± 1.8
Potassium (mmol ⋅ L−1) 4.7 ± 0.5 4.5 ± 0.3 4.4 ± 0.4 4.3 ± 0.5
chloride (mmol ⋅ L−1) 102.9 ± 1.3 103.7 ± 1.5 103.3 ± 2.1 103.4 ± 1.5
cO2 (mmol ⋅ L−1) 26.4 ± 1.6 26.9 ± 2.1 26.7 ± 1.9 26.6 ± 1.7
calcium (mg ⋅ dL−1) 9.5 ± 0.2 9.3 ± 0.2 9.3 ± 0.3 9.3 ± 0.3
Protein (g ⋅ dL−1) 6.7 ± 0.3 6.7 ± 0.3 6.6 ± 0.3 6.7 ± 0.3
Albumin (g ⋅ dL−1) 4.5 ± 0.1 4.5 ± 0.2 4.5 ± 0.2 4.5 ± 0.3
globulin (g ⋅ dL−1) 2.2 ± 0.3 2.2 ± 0.3 2.1 ± 0.2 2.2 ± 0.2
A:g 2.0 ± 0.4 2.0 ± 0.2 2.1 ± 0.2 2.1 ± 0.3
Bilirubin (mg ⋅ dL−1) 0.7 ± 0.4 0.6 ± 0.3 1.1 ± 0.8 1.0 ± 0.9
Alk Phos (IU ⋅ L−1)* 74.8 ± 22.8 70.5 ± 20.0 63.6 ± 17.1 59.9 ± 14.6
AST (SgOT) (IU ⋅ L−1) 23.9 ± 5.0 23.3 ± 3.9 23.3 ± 7.0 22.3 ± 5.9
ALT (SgPT) (IU ⋅ L−1) 23.5 ± 11.7 23.8 ± 7.7 22.6 ± 13.2 20.3 ± 10.2
ggT (IU ⋅ L−1) 19.6 ± 8.1 17.8 ± 7.0 18.9 ± 12.7 18.9 ± 13.1
notes: Values are mean ± SD. *Significant main effect for time (P , 0.05).
Table 4. Lipid panel data for men assigned to supplement (N = 12) or placebo (N = 11) for ten weeks.
Variable supplement placebo
pre post pre post
cholesterol (mg ⋅ dL−1) 163.2 ± 25.7 154.5 ± 20.6 148.5 ± 20.4 149.3 ± 21.0
Triglycerides (mg ⋅ dL−1) 88.6 ± 36.3 83.6 ± 28.3 65.2 ± 26.7 68.8 ± 19.0
hDL-c (mg ⋅ dL−1) 53.1 ± 15.6 52.5 ± 12.9 53.4 ± 16.5 50.7 ± 10.4
VLDL-c (mg ⋅ dL−1) 17.8 ± 7.4 16.6 ± 5.7 13.1 ± 5.4 13.8 ± 3.8
LDL-c (mg ⋅ dL−1)* 92.3 ± 21.6 85.2 ± 17.5 82.0 ± 14.6 84.7 ± 16.9
LDL-c/hDL-c 1.9 ± 0.7 1.7 ± 0.5 1.7 ± 0.6 1.7 ± 0.4
notes: Values are mean ± SD. *Significant interaction (P , 0.05); lower for supplement from pre to post intervention (P = 0.034).
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1,3- dimethylamylamine are marketing not only to 
men but also to women, more work using a larger 
sample of women may be considered.
The­majority­of­subjects­in­the­present­study­con-
sumed the supplement at a dosage of two scoops per 
training day. No adverse events were noted and the 
supplement­was­well-tolerated­based­on­subject­self-
report. This agrees with our prior work with this same 
supplement,­in­which­all­subjects­successfully­com-
pleted a two-week intervention period, without inci-
dent, in which two-scoops of the supplement were 
consumed daily.5
As can be viewed in Table 1, systolic blood pres-
sure increased approximately 6 mmHg with the sup-
plement, while diastolic blood pressure decreased 
approximately 4 mmHg from pre to post intervention. 
Neither­change­was­of­statistical­significance.­Heart­
rate was lower from pre to post intervention, which 
would subsequently impact the rate pressure product 
(systolic blood pressure × heart rate). That is, when 
calculating the rate pressure product values at pre 
(7245) and post (7265) intervention (using the mean 
data provided in Table 1), it is noted that values are 
near identical. This may be of interest to those with 
concern over the increase in systolic blood pressure 
and the potential for increased myocardial stress.
Findings of minimal change in heart rate and blood 
pressure (and hence, rate pressure product) have been 
noted in our two-week intervention using the same 
supplement.5 Little change in blood pressure was 
noted in our eight week intervention using another 
supplement containing 1,3-dimethylamylamine,7 
while an increase of ∼6 bpm in resting heart rate 
have been noted. Interestingly, in our two-week inter-
vention using another supplement containing 1,3-
dimethylamylamine,5 resting heart rate was decreased 
by ∼4 bpm. More work is needed to better understand 
the role of 1,3-dimethylamylamine in relation to 
hemodynamic variables.
Related to bloodborne variables, we included the 
routine panels as used as part of a physical examina-
tion (ie, complete blood count, metabolic panel, lipid 
panel). No adverse effects were noted for any mea-
sured variable, including those related to liver function 
(eg,­SGOT,­SGPT,­GGT).­Variables­were­very­ simi-
lar from pre to post intervention for the supplement 
group. Creatinine was noted to be higher from pre 
to post intervention, in particular for the supplement 
group (Table 3). This small increase may have been 
due to the inclusion of creatine within the dietary sup-
plement. The measures of triglycerides, total and LDL 
cholesterol decreased slightly from pre to post inter-
vention,­ with­ statistically­ significant­ findings­ noted­
only for LDL-C (Table 4). As with blood pressure and 
heart rate, these bloodborne data extend our prior work 
involving a two-week intervention study using the 
same supplement5 (with the exception of an increase in 
fasting blood glucose noted in our prior work), as well 
as in our eight week intervention study using a differ-
ent supplement containing 1,3-dimethylamylamine.7
Table 5. Dietary intake for men assigned to supplement (N = 12) or placebo (N = 13) for ten weeks.
Variable supplement placebo
pre post pre post
Kilocalories 2721.3 ± 468.0 2619.0 ± 705.0 2405.9 ± 561.4 2262.4 ± 457.7
Protein (g) 135.2 ± 44.5 126.5 ± 41.5 101.3 ± 27.9 110.4 ± 27.9
carbohydrate (g) 299.0 ± 93.7 295.4 ± 131.4 310.5 ± 95.2 264.1 ± 68.1
Fiber (g)* 23.9 ± 9.8 21.1 ± 12.4 21.0 ± 7.9 17.2 ± 4.7
Sugar (g) 92.4 ± 46.0 103.9 ± 62.3 97.8 ± 48.0 83.1 ± 34.3
Fat (g) 104.1 ± 18.3 101.1 ± 20.1 82.0 ± 27.3 81.8 ± 18.4
Saturated fat (g) 30.6 ± 8.2 29.4 ± 5.9 25.1 ± 11.9 24.5 ± 6.9
Monounsaturated fat (g) 22.8 ± 10.8 22.8 ± 14.2 13.6 ± 5.8 15.9 ± 4.9
Polyunsaturated fat (g) 9.7 ± 5.5 8.8 ± 4.0 6.4 ± 5.8 7.4 ± 2.8
cholesterol (mg) 412.1 ± 254.8 427.5 ± 245.0 286.1 ± 110.8 340.1 ± 178.4
Vitamin c (mg) 148.6 ± 149.6 114.6 ± 157.9 133.3 ± 99.2 109.5 ± 59.6
Vitamin e (mg) 8.1 ± 8.2 8.5 ± 8.8 5.7 ± 5.3 6.0 ± 4.6
Vitamin A (re) 382.0 ± 285.8 369.9 ± 379.2 303.3 ± 179.3 348.7 ± 235.3
Selenium (μg)* 47.6 ± 24.0 55.3 ± 34.9 42.2 ± 33.3 59.9 ± 41.8
notes: Values are mean ± SD. *Significant main effect for time (P , 0.05).
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conclusion
Findings from the present study indicate that a dietary 
supplement containing 1,3-dimethylamylamine con-
sumed­for­a­period­of­10­weeks­does­not­result­ in­a­
statistically­significant­increase­in­resting­heart­rate­or­
blood pressure in a sample of healthy men, nor does 
the supplement negatively impact bloodborne bio-
markers of health. The supplement results in a small 
decrease in LDL-C, which may suggest a potential 
cardioprotective role. While this may have clini-
cal relevance, additional studies inclusive of larger 
samples­are­needed­to­replicate­these­findings,­as­well­
as­ to­extend­and­expand­upon­other­findings­associ-
ated with this work. In particular, longer intervention 
periods and the inclusion of additional measures of 
health and toxicity are needed in future studies involv-
ing 1,3-dimethylamylamine. Finally, it should be 
noted­that­despite­our­lack­of­statistical­significance,­
the supplement did result in a mean increase in sys-
tolic blood pressure of ∼6 mmHg, indicating that it 
would be prudent for those with elevated blood pres-
sure to avoid use of dietary supplements containing 
1,3-dimethylamylamine.
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